These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 10486929)
1. Lassa fever: implications of T-cell immunity for vaccine development. ter Meulen J J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929 [TBL] [Abstract][Full Text] [Related]
2. Vaccine platforms to control Lassa fever. Lukashevich IS; Pushko P Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941 [TBL] [Abstract][Full Text] [Related]
3. Towards a human Lassa fever vaccine. Fisher-Hoch SP; McCormick JB Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670 [TBL] [Abstract][Full Text] [Related]
4. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever. Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693 [TBL] [Abstract][Full Text] [Related]
5. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice. Hashizume M; Takashima A; Iwasaki M J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352 [TBL] [Abstract][Full Text] [Related]
6. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. ter Meulen J; Badusche M; Kuhnt K; Doetze A; Satoguina J; Marti T; Loeliger C; Koulemou K; Koivogui L; Schmitz H; Fleischer B; Hoerauf A J Virol; 2000 Mar; 74(5):2186-92. PubMed ID: 10666248 [TBL] [Abstract][Full Text] [Related]
7. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628 [TBL] [Abstract][Full Text] [Related]
8. Current research for a vaccine against Lassa hemorrhagic fever virus. Warner BM; Safronetz D; Stein DR Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299 [TBL] [Abstract][Full Text] [Related]
9. Vaccine platforms for the prevention of Lassa fever. Purushotham J; Lambe T; Gilbert SC Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485 [TBL] [Abstract][Full Text] [Related]
11. Advanced vaccine candidates for Lassa fever. Lukashevich IS Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493 [TBL] [Abstract][Full Text] [Related]
12. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region. Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC mBio; 2020 Mar; 11(2):. PubMed ID: 32209677 [TBL] [Abstract][Full Text] [Related]
13. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs. Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337 [TBL] [Abstract][Full Text] [Related]
14. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model. Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368 [TBL] [Abstract][Full Text] [Related]
15. Immune responses and Lassa virus infection. Russier M; Pannetier D; Baize S Viruses; 2012 Nov; 4(11):2766-85. PubMed ID: 23202504 [TBL] [Abstract][Full Text] [Related]
16. The search for animal models for Lassa fever vaccine development. Lukashevich IS Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740 [TBL] [Abstract][Full Text] [Related]
17. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Zapata JC; Poonia B; Bryant J; Davis H; Ateh E; George L; Crasta O; Zhang Y; Slezak T; Jaing C; Pauza CD; Goicochea M; Moshkoff D; Lukashevich IS; Salvato MS Virol J; 2013 Feb; 10():52. PubMed ID: 23402317 [TBL] [Abstract][Full Text] [Related]
18. Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. Djavani M; Yin C; Lukashevich IS; Rodas J; Rai SK; Salvato MS J Hum Virol; 2001; 4(2):103-8. PubMed ID: 11437313 [TBL] [Abstract][Full Text] [Related]